ANDA For Generic Epilepsy Drug Spurs Suit Against IVAX

Law360, New York (September 24, 2005, 12:00 AM EDT) -- Belgian drugmaker UCB Societe Anonyme has sued IVAX Corporation in federal court, seeking protection of its popular epilepsy drug Keppra from generic competition before the expiration of its patent.

The suit alleges Florida-based IVAX infringed its patent by filing an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration to produce Levetiracetam, the active ingredient in Keppra.

Compelled by the Hatch-Waxman Act, IVAX informed UCB of its intentions to produce the 250 mg 500 mg and 750 mg tablets through a notice of...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.